The Manufacturers Life Insurance Company Has $16.64 Million Position in Zoetis Inc. $ZTS

Key Points

• The Manufacturers Life Insurance Company reduced its Zoetis stake by 5.9% in the second quarter, selling 14,462 shares and retaining 231,501 shares worth approximately $16.64 million. Institutional investors collectively own 92.8% of Zoetis.
• Analyst sentiment is mixed, with a consensus rating of “Hold” and an average price target of $101.08. Recent target changes included JPMorgan lowering its target to $115 and Stifel reducing its target to $80.
• Zoetis shares opened at $73.05, near their 52-week low of $71.00 and well below the $150.05 high. The company slightly exceeded quarterly earnings expectations with $1.87 EPS, while revenue of $2.47 billion fell short of estimates and declined 0.2% year over year.

The Manufacturers Life Insurance Company lessened its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 5.9% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 231,501 shares of the company's stock after selling 14,462 shares during the quarter. The Manufacturers Life Insurance Company owned 0.06% of Zoetis worth $16,636,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its position in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock valued at $754,000 after purchasing an additional 2,978 shares during the last quarter. Empowered Funds LLC increased its position in Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company's stock worth $1,859,000 after purchasing an additional 657 shares during the last quarter. Intech Investment Management LLC raised its stake in shares of Zoetis by 17.2% during the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company's stock worth $1,374,000 after purchasing an additional 1,224 shares in the last quarter. Sivia Capital Partners LLC raised its stake in shares of Zoetis by 73.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company's stock worth $522,000 after purchasing an additional 1,422 shares in the last quarter. Finally, Glenview Trust co lifted its holdings in shares of Zoetis by 11.8% during the 2nd quarter. Glenview Trust co now owns 4,780 shares of the company's stock valued at $745,000 after buying an additional 506 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently commented on ZTS shares. Cantor Fitzgerald set a $94.00 price target on Zoetis in a research note on Tuesday, August 25th. Argus reiterated a "hold" rating on shares of Zoetis in a research note on Wednesday, May 27th. JPMorgan Chase & Co. decreased their target price on shares of Zoetis from $130.00 to $115.00 and set an "overweight" rating for the company in a research report on Friday, August 7th. Stifel Nicolaus dropped their price target on shares of Zoetis from $85.00 to $80.00 and set a "hold" rating on the stock in a research note on Thursday, August 20th. Finally, Morgan Stanley set a $85.00 price target on shares of Zoetis in a report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Zoetis has a consensus rating of "Hold" and an average target price of $101.08.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $73.05 on Friday. The business's 50-day simple moving average is $75.56 and its 200-day simple moving average is $91.97. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. Zoetis Inc. has a 52 week low of $71.00 and a 52 week high of $150.05. The firm has a market cap of $30.19 billion, a price-to-earnings ratio of 12.03, a P/E/G ratio of 1.70 and a beta of 0.73.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.02. The firm had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company's revenue for the quarter was down .2% on a year-over-year basis. During the same period in the previous year, the company earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities research analysts expect that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.

The company's product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.